Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical...
Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
Nanjing Pharmaceutical Group Co., Ltd. (SHA: 600713) has unveiled a strategic plan to establish a...
Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology
Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic...
Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio
Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) is in advanced negotiations to acquire Organon & Co....
Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer
Duality Biologics (HKG: 9606), a US‑China dual‑headquartered antibody‑drug conjugate (ADC) developer, announced that the National Medical...
Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
Oricell Therapeutics Co., Ltd. announced completion of a US$110 million+ pre‑IPO financing round, positioning the cell...
Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease
Sino Biopharmaceutical Ltd (HKG: 1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating...
Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
Peijia Medical Ltd (HKG: 9996) announced completion of the first patient implant in the Early Feasibility...
Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has granted...
Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced that partner Gilead Sciences Inc. (NASDAQ: GILD) has exercised its exclusive...
Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has approved...
Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Sinocelltech Group Ltd (SHA: 688520) announced plans to raise up to RMB 900 million (US$132 million) through a...
NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform
NorrDia Medical, a Ningbo‑based blood purification specialist, announced completion of a RMB 100 million+ (US$14.6 million) financing...
Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners
Vivatides Therapeutics announced the completion of an oversubscribed USD 54 million Series A financing round,...
C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
C4 Therapeutics, Inc. (NASDAQ: CCCC), a leader in targeted protein degradation (TPD), announced an expanded...
Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis
Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products...
Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K
Thermo Fisher Scientific Inc. (NYSE: TMO), the global life sciences leader, announced a strategic collaboration...
Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia
Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral...
BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National...
Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer
Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has...